The affordability of prescription drugs is a priority issue for millions of Americans. As Election Day approaches, each side of the aisle is pursuing different approaches to bringing down drug prices. What are some of the steps a new administration – whoever wins – and a new Congress can take to reduce drug costs, spur more competition and speed up the entry of generic drugs into the market?
Join POLITICO on Thursday, Oct. 1, for a deep-dive conversation exploring a range of ideas on improving prescription drug affordability, including patent reform, how the FDA can build on its recent record of fast-tracking generic approvals and the role of international price benchmarking.
10:05 AM ET — Sponsored Segment
   Alex Brill, CEO, Matrix Global Advisors
   Moderated by: Carol Vassar, Contributing health care reporter and
   podcast host
Â
   **A sponsored session produced by the Coalition for Affordable
   Prescription Drugs
10:20 AM ET — POLITICO Editorial Panel Conversation
   Kristen Bernie, Deputy Vice President, Policy and Research
   Group, PhRMA
   Juliette Cubanski, Deputy Director, Program on Medicare Policy,
   Kaiser Family Foundation
   Stacie B. Dusetzina, PhD, Associate Professor of Health Policy,
   Ingram Associate Professor of Cancer Research, Health Policy PhD
   Program Director, Vanderbilt University School of Medicine
   Moderated by: Adriel Bettelheim, Health Care Editor, POLITICO and
   Sarah Owermohle, Senior Drug Policy Reporter, POLITICO
